Breast Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Breast Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month31 studies across 18 companies, in the next 180 days.
August 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsNCT05262400Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 1/2 | Active, not recruiting | 2026-08-23 | in 3 d | 2024-11-18 |
| AZN | AstraZeneca | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseNCT04711252Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 | Phase 3 | Active, not recruiting | 2026-08-24 | in 4 d | 2025-10-14 |
| EXEL | Exelixis | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092 | Phase 1 | Active, not recruiting | 2026-08-31 | in 11 d | 2024-11-19 |
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
September 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)NCT05548127Phase 1b: number of participants with dose limiting toxicities | Phase 1/2 | Active, not recruiting | 2026-09-01 | in 12 d | 2026-02-10 |
| PFE | Pfizer | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsNCT04557449Number of participants with dose limiting toxicities in the Dose Escalation Portion | Phase 2 | Active, not recruiting | 2026-09-23 | in 34 d | 2025-10-01 |
| AZN | AstraZeneca | HER2-positive Metastatic Breast Cancer in KazakhstanNCT07593196observational(1) To assess median PFS and PFS rate in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan | — | Not yet recruiting | 2026-09-30 | in 41 d | 2026-05-18 |
| PCSA | Processa Pharmaceuticals | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692Evaluation of Objective Response Rate (ORR) | Phase 2 | Recruiting | Sep 2026 | ≤ 41 d | 2025-06-19 |
October 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
| AZN | AstraZeneca | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsNCT06429761To assess the safety of trastuzumab deruxtecan in adult Indian patients | Phase 4 | Recruiting | 2026-10-31 | in 72 d | 2025-11-24 |
| AZN | AstraZeneca | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447Time to first subsequent treatment (TFST) of PIK3CA/AKT1/PTEN-altered population in Cohort 1 | Phase 3 | Active, not recruiting | 2026-10-31 | in 72 d | 2026-08-17 |
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
| OLMA | Olema Pharmaceuticals, Inc. | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738Dose-Selection Part: Incidence of adverse events | Phase 3 | Active, not recruiting | 2026-10-31 | in 72 d | 2026-08-13 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 | Phase 1 | Recruiting | 2026-11-23 | in 95 d | 2026-06-22 |
| ATOS | Atossa Therapeutics, Inc. | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerNCT05607004PK Cohort - (Z)-endoxifen steady-state plasma concentrations | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-08 |
December 2026 14
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)NCT05573555Phase 1b: Number of Participants With Dose Limiting Toxicities | Phase 1/2 | Active, not recruiting | 2026-12-30 | in 132 d | 2026-03-09 |
| PFE | Pfizer | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerNCT05909397Study Lead-in (SLI): Incidence of Grade 4 neutropenia | Phase 3 | Active, not recruiting | 2026-12-30 | in 132 d | 2026-02-10 |
| PFE | Pfizer | A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerNCT06495164observationalOverall Survival (OS) | — | Active, not recruiting | 2026-12-30 | in 132 d | 2025-11-25 |
| CMPX | Compass Therapeutics | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-28 |
| DOFG.OL | DOF Inc. | Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast ReconstructionNCT06555614observationalIncidence Rate(%) of Major Short-Term Complications Over 12 Weeks Post-Application of ADM | — | Recruiting | 2026-12-31 | in 133 d | 2026-04-28 |
| GILD | Gilead Sciences | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)NCT04639986Progression-free Survival (PFS) | Phase 3 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-02-09 |
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| LLY | Eli Lilly and Company | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-08-07 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| NXTC | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-12-16 |
| PFE | Pfizer | PF-07104091 as a Single Agent and in Combination TherapyNCT04553133Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 2 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-05-06 |
| PFE | Pfizer | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesNCT05226871Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs) | Phase 2 | Active, not recruiting | 2026-12-31 | in 133 d | 2025-11-25 |
| PFE | Pfizer | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364Percentage of participants with ≥1 adverse event (AE) | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-03-12 |
| PFE | Pfizer | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)NCT06125522Phase 1b: Number of Participants With Dose Limiting Toxicities | Phase 1/2 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-05-06 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4568.T | Daiichi Sankyo Co., Ltd. | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)NCT03401385Number of participants with dose-limiting toxicities | Phase 1 | Active, not recruiting | 2027-01-01 | in 134 d | 2025-10-21 |
| ELVN | Enliven Therapeutics | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerNCT06328738Incidence of dose limiting toxicities (DLTs; Phase 1a only) | Phase 1 | Active, not recruiting | Jan 2027 | ≤ 164 d | 2025-11-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Breast Cancer
most recently updated first851 studies match. Showing the first 100 of 851 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951Invasive breast cancer-free survival (IBCFS) | Phase 3 | Recruiting | Drug: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane | Breast Cancer, Early Breast Cancer | 4,300 | 2023-03-31 | 2027-04-20 | in 243 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent | Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer | 399 | 2023-12-01 | Nov 2028 | ≤ 833 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,139 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerNCT07408089Rate of dose limiting toxicities (DLTs) in each BBI-940 monotherapy dose escalation cohort. | Phase 1 | Terminatedsponsor's stated reason: The study was terminated primarily due to a business decision related to a corporate transaction and was not driven by any safety signal. | Drug: BBI-940, Fulvestrant | Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer | 8 | 2026-02-25 | 2026-07-28actual | — | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib | HR+/HER2- Breast Cancer | 1,056 | 2026-05-22 | Apr 2029 | ≤ 984 d | 2026-08-19 |
| AZN | AstraZeneca | — | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.NCT03616587The number of subjects with dose-limiting toxicity, as defined in the protocol. | Phase 1 | Active, not recruiting | Drug: AZD9833, AZD9833, AZD9833 with palbociclib, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with everolimus, AZD9833 with abemaciclib, AZD9833 with abemaciclib, AZD9833 with capivasertib, AZD9833 with capivasertib, AZD9833 with ribociclib, AZD9833 with ribociclib, AZD9833 with anastrozole, AZD9833 with anastrozole | ER+ HER2- Advanced Breast Cancer | 396 | 2018-10-11 | 2024-09-16actual | — | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsNCT06618287Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig | Lung Cancer, Breast Cancer | 416 | 2025-02-04 | 2031-02-26 | in 1,651 d | 2026-08-18 |
| CNTX | Context Therapeutics Inc. | $49M | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersNCT07545122Phase 1a: Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: CT-202 | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | 162 | Sep 2026 | Jan 2030 | ≤ 1,260 d | 2026-08-18 |
| INCY | Incyte Corporation | $24.7B | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940Frequency and types of adverse events and serious adverse events | Phase 2 | Active, not recruiting | Drug: Ruxolitinib, Capecitabine, Regorafenib | Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer | 10 | 2016-11-30 | 2027-09-30 | in 406 d | 2026-08-17 |
| AZN | AstraZeneca | — | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol. | Phase 3 | Active, not recruiting | Drug: Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib | Locally Advanced (Inoperable) or Metastatic Breast Cancer | 893 | 2021-05-10 | 2027-11-01 | in 438 d | 2026-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| BCTX | BriaCell Therapeutics Corporation | $31M | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612Overall Survival | Phase 3 | Recruiting | Biological: SV-BR-1-GM · Drug: Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice | Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer | 404 | 2023-12-05 | Dec 2027 | ≤ 498 d | 2026-08-17 |
| AZN | AstraZeneca | — | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447Time to first subsequent treatment (TFST) of PIK3CA/AKT1/PTEN-altered population in Cohort 1 | Phase 3 | Active, not recruiting | Drug: Capivasertib, Fulvestrant | Breast Cancer | 293 | 2024-09-26 | 2026-10-31 | in 72 d | 2026-08-17 |
| AZN | AstraZeneca | — | Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerNCT06727227observationalReal-world Time to Next Treatment (rwTTNT1, median, 95% CI, measured in months) | — | Recruiting | Drug: trastuzumab deruxtecan | Breast Cancer | 138 | 2025-01-29 | 2027-10-31 | in 437 d | 2026-08-17 |
| OLMA | Olema Pharmaceuticals, Inc. | $932M | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767Progression-Free Survival (PFS) | Phase 3 | Recruiting | Drug: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo | Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma | 1,000 | 2025-11-03 | Dec 2028 | ≤ 864 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| ALXO | ALX Oncology Inc. | $288M | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment | Phase 2 | Recruiting | Drug: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine | Breast Cancer, Metastatic | 120 | 2025-12-10 | Dec 2027 | ≤ 498 d | 2026-08-14 |
| ONC | BeOne Medicines | $545.6B | An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267Part 1: Number of Participants with Adverse Events (AEs) | Phase 1 | Recruiting | Drug: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor | Breast Cancer, Advanced Solid Tumor | 86 | 2025-12-11 | 2029-09-30 | in 1,137 d | 2026-08-14 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: GTAEXS617, SoC | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC) | 230 | 2023-07-06 | Jan 2028 | ≤ 529 d | 2026-08-13 |
| OLMA | Olema Pharmaceuticals, Inc. | $932M | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738Dose-Selection Part: Incidence of adverse events | Phase 3 | Active, not recruiting | Drug: Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma | 510 | 2023-11-16 | 2026-10-31 | in 72 d | 2026-08-13 |
| NTRA | Natera, Inc. | $44.9B | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerNCT07214532Invasive Disease-Free Survival | Not applicable | Recruiting | Device: ctDNA-Guided Treatment Strategy | Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement) | 725 | 2026-05-08 | 2037-11-15 | in 4,105 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) | Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | 460 | 2021-10-18 | 2027-09-29 | in 405 d | 2026-08-12 |
| AZN | AstraZeneca | — | PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanNCT05573893observationalReal-world Time To Next Treatment (rwTTNT1) | — | Recruiting | — | Breast Neoplasms, Breast Cancer, Neoplasm Metastasis | 800 | 2023-09-12 | 2031-12-31 | in 1,959 d | 2026-08-12 |
| RADX | Radiopharm Theranostics, Ltd | — | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.NCT07272642To assess the safety and tolerability of a single dose of LNTH-2403 | Phase 1 | Not yet recruiting | Drug: LNTH-2403 | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC) | 16 | 2026-10-30 | 2027-08-30 | in 375 d | 2026-08-12 |
| AZN | AstraZeneca | — | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerNCT04739761results2025-05-16Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline) | Phase 3 | Active, not recruiting | Drug: Trastuzumab Deruxtecan | Breast Cancer | 506 | 2021-06-22 | 2024-02-08actual | — | 2026-08-11 |
| AZN | AstraZeneca | — | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerNCT05113251results2026-06-09Rate of Pathologic Complete Response (pCR). | Phase 3 | Active, not recruiting | Drug: Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide | Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer | 927 | 2021-10-25 | 2025-03-12actual | — | 2026-08-11 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| AZN | AstraZeneca | — | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557Invasive breast cancer-free survival (IBCFS) | Phase 3 | Active, not recruiting | Drug: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib | Breast Cancer, Early Breast Cancer | 5,511 | 2023-10-05 | 2030-03-04 | in 1,292 d | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868Progression-Free Survival (PFS) | Phase 2/3 | Recruiting | Drug: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine | Breast Neoplasms | 600 | 2025-09-11 | 2028-03-13 | in 571 d | 2026-08-10 |
| AZN | AstraZeneca | — | BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine TherapyNCT07597993observationalreal-world progression-free survival | — | Recruiting | Drug: TDxd | Breast Cancer | 109 | 2026-07-12 | 2029-03-31 | in 954 d | 2026-08-10 |
| AZN | AstraZeneca | — | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328Efficacy of camizestrant and ribociclib by time to next treatment (TTNT) | Phase 3 | Recruiting | Drug: Camizestrant, Ribociclib | ER-Positive HER2-Negative Breast Cancer | 150 | 2026-06-15 | 2029-02-28 | in 923 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel | Breast Cancer | 260 | 2022-05-11 | Dec 2026 | ≤ 133 d | 2026-08-07 |
| AZN | AstraZeneca | — | Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerNCT07427394Number of participants with adverse events (AEs) and serious AEs | Phase 2 | Recruiting | Drug: Camizestrant, Atirmociclib | Advanced Breast Cancer | 24 | 2026-05-06 | 2027-12-29 | in 496 d | 2026-08-07 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| GLSI | Greenwich LifeSciences, Inc. | $253M | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916Invasive Breast Cancer-free Survival (IBCFS) | Phase 3 | Recruiting | Biological: Placebo, GLSI-100 | Breast Cancer | 2,250 | 2022-12-16 | Dec 2031 | ≤ 1,959 d | 2026-08-06 |
| AZN | AstraZeneca | — | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours | Phase 1 | Recruiting | Biological: NT-175 | Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS) | 45 | 2023-07-12 | 2029-07-31 | in 1,076 d | 2026-08-06 |
| AZN | AstraZeneca | — | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsNCT06188520Incidence of dose limiting toxicities (DLTs) as defined in the protocol. | Phase 1/2 | Recruiting | Drug: AZD8421, Camizestrant, Ribociclib, Palbociclib, Abemaciclib | ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC) | 564 | 2023-12-05 | 2027-08-04 | in 349 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496 | Phase 1 | Recruiting | Drug: LY4257496, Standard of Care Anticancer Therapies · Diagnostic test: LY4257529 | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms | 421 | 2025-08-06 | Apr 2030 | ≤ 1,349 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336(Part 1): Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR) | Phase 3 | Recruiting | Drug: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant | Breast Neoplasms, Neoplasm Metastasis | 800 | 2025-12-22 | May 2029 | ≤ 1,015 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities | Phase 1 | Recruiting | Drug: LY4337713 | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma | 241 | 2025-10-22 | Jul 2028 | ≤ 711 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098Change from Baseline in Antigen Kiel (Ki-67) Expression | Phase 2 | Recruiting | Drug: Imlunestrant, Goserelin, Tamoxifen 20 mg | Breast Neoplasms | 600 | 2026-05-13 | Jan 2029 | ≤ 895 d | 2026-08-06 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723Phase 1: Safety Assessment | Phase 1/2 | Not yet recruiting | Biological: IOV-5001 | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor | 106 | Aug 2026 | Mar 2034 | ≤ 2,780 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| RLAY | Relay Therapeutics, Inc. | $4.5B | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521Progression-Free Survival (PFS) within the overall and kinase population by blinded independent central review (BICR) | Phase 3 | Recruiting | Drug: Zovegalisib, Capivasertib, Fulvestrant | PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer | 540 | 2025-08-26 | 2028-04-30 | in 619 d | 2026-08-05 |
| AZN | AstraZeneca | — | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerNCT03742102results2026-02-02Dose Limiting Toxicity (DLT) Events | Phase 1/2 | Active, not recruiting | Drug: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan | Triple Negative Breast Neoplasms | 243 | 2018-12-21 | 2024-11-29actual | — | 2026-08-04 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-400, Itraconazole (ITZ), Bevacizumab | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | 302 | 2023-11-09 | Sep 2027 | ≤ 406 d | 2026-08-04 |
| AZN | AstraZeneca | — | A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.NCT07743944observationalPercentage of patients receiving different regimens in each Line of treatment (LoT) | — | Recruiting | — | Breast Cancer | 2,000 | 2026-08-05 | 2031-08-04 | in 1,810 d | 2026-08-04 |
| AZN | AstraZeneca | — | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerNCT04556773Occurrence of adverse events (AEs)- Part 1 | Phase 1 | Active, not recruiting | Drug: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine | Metastatic Breast Cancer | 138 | 2020-12-17 | 2023-08-16actual | — | 2026-08-03 |
| BNTX | BioNTech SE | — | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerNCT07173751Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo | Breast Neoplasms | 558 | 2025-10-30 | Dec 2029 | ≤ 1,229 d | 2026-08-03 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| AZN | AstraZeneca | — | Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751Progression-Free Survival (Arm 1 vs arm 2) | Phase 3 | Recruiting | Drug: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane | Advanced Breast Cancer | 788 | 2024-08-01 | 2029-12-18 | in 1,216 d | 2026-07-30 |
| AZN | AstraZeneca | — | Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST CancerNCT07070128observationalAgreement between AI tool results and genetic test results | — | Recruiting | — | Breast Neoplasms | 800 | 2025-08-20 | 2026-08-11 | — | 2026-07-29 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Drug: CTX-8371 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma | 85 | 2024-03-19 | Dec 2026 | ≤ 133 d | 2026-07-28 |
| PBYI | Puma Biotechnology, Inc. | $477M | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285Objective Response Rate (ORR) Within Dose Subgroup | Phase 2 | Recruiting | Drug: Alisertib, Endocrine therapy | Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer | 225 | 2024-11-19 | 2027-12-30 | in 497 d | 2026-07-27 |
| AZN | AstraZeneca | — | A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerNCT07205822Progression Free Survival (PFS) per RECIST 1.1 as assessed by the investigator | Phase 3 | Recruiting | Drug: Dato-DXd | Breast Cancer | 100 | 2025-10-30 | 2028-02-02 | in 531 d | 2026-07-27 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647results2024-07-30Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment | Phase 3 | Active, not recruiting | Drug: tucatinib, placebo, T-DM1 | HER2-positive Breast Cancer | 466 | 2019-10-02 | 2023-06-29actual | — | 2026-07-23 |
| AZN | AstraZeneca | — | 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)NCT04553926observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions(ADRs), serious ADRs (SADRs), unexpected AEs/ADRs) | — | Completed | — | Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer | 661 | 2021-02-01 | 2025-07-11actual | — | 2026-07-23 |
| 4568.T | Daiichi Sankyo | $31.7B | T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdNCT07683754Progression-free Survival (PFS) Rate at 24 Months | Phase 3 | Not yet recruiting | Drug: Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib | Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive | 200 | 2026-09-04 | 2030-07-04 | in 1,414 d | 2026-07-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308results2025-07-11Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) | Phase 3 | Active, not recruiting | Drug: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib | Breast Neoplasms, Neoplasm Metastasis | 874 | 2021-10-04 | 2024-06-24actual | — | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Phase 3 | Active, not recruiting | Drug: Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo | HER2 Positive Breast Cancer | 654 | 2022-03-07 | 2025-09-05actual | — | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892Number of participants with dose limiting toxicities (DLTs) in dose escalation phase | Phase 2 | Active, not recruiting | Drug: disitamab vedotin, tucatinib | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | 54 | 2024-05-20 | 2029-07-28 | in 1,073 d | 2026-07-22 |
| AZN | AstraZeneca | — | Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.NCT06417801observationalPrevalence of emerging ESR1 mutations | — | Recruiting | — | Metastatic Breast Cancer | 170 | 2024-06-17 | 2027-12-30 | in 497 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT) | Phase 1 | Recruiting | Drug: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab | Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer | 260 | 2025-12-23 | 2029-04-14 | in 968 d | 2026-07-22 |
| CNTX | Context Therapeutics Inc. | $49M | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerNCT05618613results2026-07-21Number of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision to discontinue onapristone development. | Drug: Elacestrant, Onapristone | Breast Cancer | 4 | 2022-12-02 | 2023-06-23actual | — | 2026-07-21 |
| BNTX | BioNTech SE | — | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerNCT06827236Part 1 - Occurrence of dose limiting toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: BNT323, BNT327 | Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer | 380 | 2025-04-23 | Aug 2029 | ≤ 1,107 d | 2026-07-21 |
| AZN | AstraZeneca | — | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864Progression Free Survival (PFS) | Phase 3 | Recruiting | Drug: Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab | Breast Cancer | 625 | 2023-11-23 | 2027-07-28 | in 342 d | 2026-07-20 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerNCT04572295Part 1: Recommended Dose (RD) of E7090 in Combination With Other Anticancer Agents | Phase 1 | Completed | Drug: E7090, Fulvestrant, Exemestane | Breast Neoplasms | 51 | 2020-10-09 | 2026-06-18actual | — | 2026-07-17 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654Invasive Disease-free Survival (iDFS) | Phase 3 | Recruiting | Drug: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine | Triple Negative Breast Cancer | 1,514 | 2022-12-12 | Jun 2027 | ≤ 314 d | 2026-07-15 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopauseNCT06465368results2026-07-15Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 | Phase 2 | Completed | Drug: PF-07220060, letrozole | Breast Cancer | 121 | 2024-07-11 | 2025-07-10actual | — | 2026-07-15 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Number of participants with pCR | Phase 2 | Recruiting | Drug: Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab | HER2-positive Breast Cancer, Breast Cancer | 125 | 2025-09-24 | 2028-01-01 | in 499 d | 2026-07-15 |
| AZN | AstraZeneca | — | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823results2021-12-08Invasive Disease Free Survival (IDFS) | Phase 3 | Active, not recruiting | Drug: Olaparib, Placebo | Breast Cancer | 1,837 | 2014-04-22 | 2020-03-27actual | — | 2026-07-14 |
| AZN | AstraZeneca | — | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) | Phase 3 | Active, not recruiting | Drug: AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib | ER-Positive HER2-Negative Breast Cancer | 315 | 2021-06-30 | 2025-06-30actual | — | 2026-07-14 |
| AZN | AstraZeneca | — | SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBCNCT07701070observationalPrevalence of ESR1 mutations in circulating tumour DNA | — | Not yet recruiting | Other: Blood sampling | Advanced Breast Cancer | 3,000 | 2026-09-30 | 2029-03-30 | in 953 d | 2026-07-14 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | 2023-04-18 | Oct 2026 | ≤ 72 d | 2026-07-13 |
| AZN | AstraZeneca | — | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379Event-free survival (EFS) in the experimental vs control arms | Phase 3 | Active, not recruiting | Drug: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib | Breast Cancer | 1,902 | 2023-11-14 | 2028-11-20 | in 823 d | 2026-07-13 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 | Phase 1/2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer | 135 | 2021-10-20 | May 2027 | ≤ 284 d | 2026-07-10 |
| PFE | Pfizer | $155.3B | A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other OrgansNCT06003114observationalEstimate the median Duration of Treatment (DoT) | — | Completed | Drug: Palbociclib | Breast Cancer | 472 | 2023-10-06 | 2024-02-22actual | — | 2026-07-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: BMS-986500, Palbociclib, Fulvestrant | Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer | 234 | 2025-08-01 | 2028-12-14 | in 847 d | 2026-07-10 |
| AKTS | Aktis Oncology, Inc. | — | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117Part 1: Number of Patients with Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer | 150 | 2025-08-22 | Dec 2027 | ≤ 498 d | 2026-07-10 |
| PFE | Pfizer | $155.3B | A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese MarketNCT07096024observationalThe hazard ratios of ILD in palbociclib plus fulvestrant to new users of fulvestrant alone | — | Completed | Drug: palbociclib plus fulvestrant, fulvestrant | Breast Neoplasms | 95,637 | 2025-01-21 | 2025-02-07actual | — | 2026-07-10 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449results2026-07-09Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin | Phase 1 | Completed | Drug: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer | 353 | 2013-11-15 | 2019-02-19actual | — | 2026-07-09 |
| IMNM | Immunome, Inc. | $3.1B | A Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Recruiting | Drug: IM-1617 | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | 175 | 2026-05-21 | Jan 2029 | ≤ 895 d | 2026-07-09 |
| ATOS | Atossa Therapeutics, Inc. | $26M | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerNCT05607004PK Cohort - (Z)-endoxifen steady-state plasma concentrations | Phase 2 | Active, not recruiting | Drug: (Z)-endoxifen, goserelin | Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer | 87 | 2023-02-14 | Nov 2026 | ≤ 102 d | 2026-07-08 |
| AZN | AstraZeneca | — | HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in CanadaNCT06386263observationalEarly treatment discontinuation rates | — | Completed | Drug: Trastuzumab deruxtecan | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-positive Breast Cancer | 22 | 2024-04-22 | 2025-07-07actual | — | 2026-07-08 |
| AZN | AstraZeneca | — | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast CancerNCT05498155To evaluate the efficacy, measured by pCR (pathological complete response) rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy, as assessed by central pathology review. | Phase 2 | Active, not recruiting | Drug: Neoadjuvant Olaparib monotherapy group · Combination product: Neoadjuvant combination therapy with olaparib plus durvalumab | Breast Cancer | 50 | 2022-11-07 | 2024-11-20actual | — | 2026-07-07 |
| LLY | Eli Lilly and Company | $1.15T | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139Number of participants who experience at least 1 Dose Limiting Toxicity (DLT) | Phase 1/2 | Recruiting | Drug: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin | Breast Cancer, Solid Tumors, Adult | 880 | 2023-04-17 | Jul 2030 | ≤ 1,441 d | 2026-07-07 |
| AZN | AstraZeneca | — | REBECCA Real-world Early BrEast CanCer mAnagementNCT06856343observationalProportion of patients who receive Olaparib for the full treatment duration | — | Recruiting | — | Breast Cancer | 126 | 2024-12-30 | 2028-01-31 | in 529 d | 2026-07-07 |
| AZN | AstraZeneca | — | CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREANCT06927648observationalAdverse Events (AEs)·Adverse Drug Reactions (ADRs) Serious Adverse Events (SAEs)·Adverse Drug Reactions (SADRs) Unexpected Adverse Events (AEs)·Adverse Drug Reactions (ADRs) | — | Recruiting | — | Breast Cancer | 130 | 2025-10-15 | 2029-12-30 | in 1,228 d | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| AZN | AstraZeneca | — | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.NCT03330847results2022-03-22Progression-free Survival Per Stratum (BICR) | Phase 2 | Active, not recruiting | Drug: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). | Metastatic Triple Negative Breast Cancer | 273 | 2018-03-07 | 2020-11-13actual | — | 2026-07-02 |
| AZN | AstraZeneca | — | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)NCT05460273results2025-06-13Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR) | Phase 1/2 | Active, not recruiting | Drug: Datopotamab Deruxtecan (Dato-DXd) | Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer | 119 | 2022-07-11 | 2023-11-07actual | — | 2026-07-02 |
| COGT | Cogent Biosciences, Inc. | $6.4B | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsNCT07383506Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Phase 1a] | Phase 1 | Recruiting | Drug: CGT6297 | PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer | 90 | Jun 2026 | Jul 2029 | ≤ 1,076 d | 2026-07-01 |
| PFE | Pfizer | $155.3B | European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal TherapiesNCT05043506observationalReal-world progression free survival | — | Completed | Drug: Palbociclib + aromatase inhibitor, Aromatase inhibitor | Metastatic Breast Cancer | 1,939 | 2022-02-08 | 2023-11-02actual | — | 2026-06-30 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)NCT05912933observationalNumber of Participants With/Without Hepatic Impairment for Grade 4 Neutropenia in New Users of Palbociclib | — | Completed | — | Breast Cancer | 1,342 | 2024-08-19 | 2024-08-30actual | — | 2026-06-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Breast Cancer is matched — 57 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Breast Cancer
- Breast Neoplasms
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- Advanced Breast Cancer
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- Triple Negative Breast Neoplasms
- Triple Negative Breast Cancer (TNBC)
- Triple-negative Breast Cancer
- Breast Cancer Metastatic
- Breast Carcinoma
- Breast Neoplasm
- TNBC - Triple-Negative Breast Cancer
- Breast Cancer Female
- Cancer of Breast
- Cancer of the Breast
- Hormone-receptor-positive Breast Cancer
- Locally Advanced Breast Cancer
- Advanced or Metastatic Breast Cancer
- Breast Tumor
- Early Breast Cancer
- Bone Metastases in Subjects With Advanced Breast Cancer
- Breast Tumors
- ER+ Breast Cancer
- ER+ HER2- Advanced Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Locally Recurrent and Metastatic Breast Cancer
- Malignant Neoplasm of Breast
- Tumors, Breast
- ER-Positive HER2-Negative Breast Cancer
- HER2-low Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Malignant Tumor of Breast
- Metastatic Triple Negative Breast Cancer
- Metastatic Triple-Negative Breast Carcinoma
- Recurrent Breast Cancer
- TNBC, Triple Negative Breast Cancer
- Advanced/Metastatic HER2-negative Breast Cancer
- Breast Cancer Nos Metastatic Recurrent
- Breast Cancer, Early Breast Cancer
- Breast Cancer, Metastatic
- ER Positive Breast Cancer
- ER/PR Positive Breast Cancer
- ER/PR(+), Her2(-) Breast Cancer
- HER-2 Positive Breast Cancer
- HER2 Negative Breast Carcinoma
- HER2 Negative Breast Neoplasms
- HER2 Positive Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- HR+/HER2- Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Metastatic HER2+ Advanced Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Breast Cancer” (a text search, wider than this page)